Evidence map›Paper›PMID 41988193›Full record

ReviewFrontiers in immunology2026

The central regulator HIF-1α in digestive system pathologies: inflammation and cancer.

Guoyou Gou, Min Wen, Guonian Li, Feihong Shu, Fang Wang, Youjia Liu, Rui Xie, Jingyu Xu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guoyou Gou *Zunyi Medical University, Zunyi, China.
Min Wen *Zunyi Medical University, Zunyi, China.
Guonian LiZunyi Medical University, Zunyi, China.
Feihong ShuZunyi Medical University, Zunyi, China.
Fang WangZunyi Medical University, Zunyi, China.
Youjia LiuZunyi Medical University, Zunyi, China.
Rui XieZunyi Medical University, Zunyi, China.
Jingyu XuZunyi Medical University, Zunyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia-inducible factor-1α (HIF-1α) is a critical transcriptional regulator that allows cells to detect and respond to hypoxic conditions. Its stabilized expression and prolonged activation significantly contribute to the development and progression of inflammatory diseases and malignancies within the digestive system. In the context of inflammation, HIF-1α plays a pivotal role in the pathogenesis of various disorders-including periodontitis, eosinophilic esophagitis, viral hepatitis, pancreatitis, and inflammatory bowel disease-by modulating the expression of inflammatory mediators, driving cellular metabolic reprogramming, and influencing tissue barrier function. In terms of tumor biology, this review synthesizes pan-cancer analysis data to summarize the expression patterns of HIF-1α in major gastrointestinal malignancies, including esophageal, gastric, pancreatic, hepatocellular, and colorectal cancers. It elucidates HIF-1α's role in directly promoting tumor cell proliferation, invasion, and drug resistance, while also remodeling the tumor microenvironment to regulate immune responses. We dissect how HIF-1α cooperatively drives the formation of an immunosuppressive microenvironment, thereby influencing the efficacy of immunotherapy. This review aims to integrate the regulatory networks and molecular mechanisms of HIF-1α in digestive system inflammation, tumors, and their immune microenvironment, ultimately providing novel theoretical foundations and strategic insights for targeted therapies and immune interventions in related diseases.

Indexed as

Digestive System DiseasesDigestive System NeoplasmsHypoxia-Inducible Factor 1, alpha SubunitInflammationAnimalsHumansTumor MicroenvironmentHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitcancerdigestiveHIF-1αinflammationtumor-associated immune cells

Identifiers

PMID41988193
PMCPMC13077602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.